BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 10997815)

  • 21. Efficacious but insidious: a retrospective analysis of fludarabine-induced myelotoxicity using long-term culture-initiating cells in 100 follicular lymphoma patients.
    Janikova A; Koristek Z; Vinklarkova J; Pavlik T; Sticha M; Navratil M; Kral Z; Vasova I; Mayer J
    Exp Hematol; 2009 Nov; 37(11):1266-73. PubMed ID: 19654036
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma.
    McLaughlin P; Hagemeister FB; Romaguera JE; Sarris AH; Pate O; Younes A; Swan F; Keating M; Cabanillas F
    J Clin Oncol; 1996 Apr; 14(4):1262-8. PubMed ID: 8648382
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma.
    Czuczman MS; Koryzna A; Mohr A; Stewart C; Donohue K; Blumenson L; Bernstein ZP; McCarthy P; Alam A; Hernandez-Ilizaliturri F; Skipper M; Brown K; Chanan-Khan A; Klippenstein D; Loud P; Rock MK; Benyunes M; Grillo-Lopez A; Bernstein SH
    J Clin Oncol; 2005 Feb; 23(4):694-704. PubMed ID: 15681517
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group].
    Forstpointner R; Hänel A; Repp R; Hermann S; Metzner B; Pott C; Hartmann F; Rothmann F; Böck HP; Wandt H; Unterhalt M; Hiddemann W
    Dtsch Med Wochenschr; 2002 Oct; 127(43):2253-8. PubMed ID: 12397539
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Evaluation of the clinical effectivity and toxicity of the FDN regimen (fludarabin, mitoxantron, dexamethason) in patients with follicular lymphoma].
    Oborilová A; Mayer J; Korístek Z; Hofmanová Z; Vásová I; Navrátil M; Vinklárková J; Muzikárová M; Klabusay M; Matuska M
    Cas Lek Cesk; 2004; 143(10):685-90. PubMed ID: 15584619
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fludarabine, adriamycin and dexamethasone (FAD) in newly diagnosed advanced follicular lymphoma: a phase II study by the British National Lymphoma Investigation (BNLI).
    Yung L; Cunningham D; Hancock B; Smith P; Maclennan K; Linch D; McMillan A
    Br J Cancer; 2004 Aug; 91(4):695-8. PubMed ID: 15280929
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma.
    Karmali R; Kassar M; Venugopal P; Shammo JM; Fung HC; Bayer R; O'Brien T; Gregory SA
    Clin Lymphoma Myeloma Leuk; 2011 Dec; 11(6):467-74. PubMed ID: 21700527
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Preliminary report of fludarabine, mitoxantrone and dexamethasone in treating refractory or relapsed multiple myeloma].
    Luo SK; Li J; Hong WD; Zhao Y; Tong XZ
    Ai Zheng; 2005 Dec; 24(12):1518-21. PubMed ID: 16351805
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of indolent lymphoma with fludarabine/mitoxantrone combination: a phase II trial.
    Emmanouilides C; Rosen P; Rasti S; Territo M; Kunkel L
    Hematol Oncol; 1998 Sep; 16(3):107-16. PubMed ID: 10235069
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of fludarabine and mitoxantrone (FN) combination regimen in untreated indolent non-Hodgkin's lymphomas.
    Zinzani PL; Magagnoli M; Bendandi M; Gherlinzoni F; Orcioni GF; Cellini C; Stefoni V; Pileri SA; Tura S
    Ann Oncol; 2000 Mar; 11(3):363-5. PubMed ID: 10811507
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Linfomi.
    Vitolo U; Ladetto M; Boccomini C; Baldini L; De Angelis F; Tucci A; Botto B; Chiappella A; Chiarenza A; Pinto A; De Renzo A; Zaja F; Castellino C; Bari A; Alvarez De Celis I; Evangelista A; Parvis G; Gamba E; Lobetti-Bodoni C; Ciccone G; Rossi G
    J Clin Oncol; 2013 Sep; 31(27):3351-9. PubMed ID: 23960180
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low-grade non-Hodgkin's lymphoma--development of a new effective combination regimen (fludarabine, mitoxantrone and dexamethasone; FND).
    Keating MJ; McLaughlin P; Cabanillas F
    Eur J Cancer Care (Engl); 1997 Dec; 6(4 Suppl):21-6. PubMed ID: 9460339
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Experience with fludarabine treatment and review of the literature].
    Telek B; Rejtó L; Kiss A; Batár P; Reményi G; Rák K; Udvardy M
    Orv Hetil; 2002 Jun; 143(24):1459-65. PubMed ID: 12138643
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mitoxantrone and fludarabine in the treatment of patients with non-Hodgkin's lymphoma failing primary therapy with a doxorubicinor mitoxantrone-containing regimen.
    Gregory SA; Vose J; Modiano M; Kraemer K; Rifkin R; Rubin A; Menduni T; Ghalie R
    Leuk Lymphoma; 2001 Jan; 40(3-4):315-24. PubMed ID: 11426553
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fludarabine-Mitoxantrone-Rituximab regimen in untreated indolent non-follicular non-Hodgkin's lymphoma: experience on 143 patients.
    Zinzani PL; Pellegrini C; Broccoli A; Gandolfi L; Stefoni V; Casadei B; Maglie R; Argnani L; Pileri S
    Hematol Oncol; 2015 Sep; 33(3):141-6. PubMed ID: 24986783
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Treatment of lymphoma patients with fludarabine-based regimens: a report of 29 cases].
    Huang HQ; Jiang WQ; Peng YL; Xia ZJ; Li YH; Li XB; Lin TY; Sun XF; Guan ZZ
    Ai Zheng; 2004 Apr; 23(4):448-51. PubMed ID: 15087037
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fludarabine, mitoxantrone and dexamethasone as first-line treatment for T-cell large granular lymphocyte leukemia.
    Tse E; Chan JC; Pang A; Au WY; Leung AY; Lam CC; Kwong YL
    Leukemia; 2007 Oct; 21(10):2225-6. PubMed ID: 17525720
    [No Abstract]   [Full Text] [Related]  

  • 38. Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma.
    Hendry L; Bowen A; Matutes E; Swansbury J; Catovsky D
    Leuk Lymphoma; 2004 May; 45(5):945-50. PubMed ID: 15291353
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia.
    Schmitt B; Wendtner CM; Bergmann M; Busch R; Franke A; Pasold R; Schlag R; Hopfinger G; Hiddemann W; Emmerich B; Hallek M
    Clin Lymphoma; 2002 Jun; 3(1):26-35. PubMed ID: 12141952
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma).
    Zinzani PL; Derenzini E; Pellegrini C; Rigacci L; Fabbri A; Gandolfi L; Argnani L; Casadei B; Pulsoni A; Gobbi M; Perotti A; Zaccaria A; Voso MT; Cabras MG; De Renzo A
    Ann Oncol; 2012 Mar; 23(3):805-807. PubMed ID: 22287683
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.